In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.


This content is currently on FREE ACCESS, enjoy another 18 days of free consultation

In these unprecedented times, the ESC is doing everything it can to support its community: FREE access to all ESC 365 content until 31 July: explore more than 125,000 educational resources.

From 1 August onwards, support our mission by becoming a member.

Severe functional mitral valve regurgitation and right ventricular dysfunction as independent predictors of poor response in HF patients after CRT therapy implementation.

Session Poster session 1

Speaker Eftihia Simeonidou

Event : EHRA 2019

  • Topic : arrhythmias and device therapy
  • Sub-topic : Cardiac Resynchronization Therapy
  • Session type : Poster Session

Authors : E Simeonidou (Athens,GR), C Pantsios (Athens,GR), G Giannakakis (Athens,GR), V Mpistola (Athens,GR), J Parissis (Athens,GR), G Filippatos (Athens,GR), E Iliodromitis (Athens,GR)

Authors:
E Simeonidou1 , C Pantsios1 , G Giannakakis1 , V Mpistola1 , J Parissis1 , G Filippatos1 , E Iliodromitis1 , 1Attikon University Hospital, 2nd University Cardiology Dept - Athens - Greece ,

Citation:

Purpose: Although cardiac resynchronization therapy (CRT) in severe heart failure (HF) patients (pts) was expected to improve functional mitral regurgitation (FMR) by the induction of reverse remodeling, not all pts manifest MR reduction. Additionally, there is evidence of inverse association between right ventricular dysfunction (RVD) and response to CRT. Aim of the study was to evaluate the impact of severe FMR associated with severe right ventricular dysfunction to the outcome of HF status in pts receiving CRTD.

Methods: The study population consisted of 67 severe HF pts with LBBB, on optimal medical treatment, who received CRTD, (10?  and 57?), mean age 61±15 years, 33 with underlying disease ischemic cardiomyopathy and 34 with dilated cardiomyopathy. Most of them underwent optimization of CRT parameters at rest and on exercise. They underwent clinical evaluation and echocardiography assessment of LV dimensions, LVEF, MR quantification, RV dimensions, RVEF and tricuspid annular plane systolic excursion (TAPSE) before CRTD, after 6 months and long-term (6±2 years). Baseline FMR was present in 88% of pts (mild 20, moderate 30, severe 9 pts), severe RVD in 7pts (TAPSE<15mm).

Results: Forty-eight pts were CRT good clinical responders, 8 super responders and 11 pts poor responders. Twenty-three pts with moderate MR and 1 out of 9 pts with severe MR were good responders with early improvement of MR. Six pts (poor responders, severe FMR and severe RVD) died of pump failure. Two pts underwent surgical MR repair and 2 Percutaneous Mitral Clip with mild improvement of MR and HF. Severe baseline FMR and RVD TAPSE<15mm) were associated with hospital readmissions and poor survival (Kaplan-Meier analysis, p<0.001).

Conclusion: Severe baseline FMR and RVD are independent harbingers of resistant HF, unresponsive to CRT implementation and are associated with hospital readmissions and increased mortality and morbidity.

This content is currently on FREE ACCESS, enjoy another 18 days of free consultation

In these unprecedented times, the ESC is doing everything it can to support its community: FREE access to all ESC 365 content until 31 July: explore more than 125,000 educational resources.

From 1 August onwards, support our mission by becoming a member.



Based on your interests

Members get more

Join now
  • 1ESC Professional Members – access all resources from general ESC events 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are